Lorna Rodriguez-Rodriguez, M.D., Ph.D.
- Gynecologic Malignancies, Surgery & Chemotherapy
- Ovarian Cancer
- Vulvar Cancer
- Endometrial Cancer
- Cervical Cancer
- Clinical Trials
- Immunotherapy
- Cellular Therapy/CAR T Cell
- Ovarian Cancer
- Vice Chair of Faculty Development
- Professor, Division of Gynecologic Oncology, Department of Surgery
I am determined to work in finding ways to make women with ovarian cancer feel better and I definitely hope to find a cure someday soon.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
1988-present, Certificate of Special Competence in Gynecological Oncology
1987-present, American Board of Obstetrics and Gynecology
1996, Biochemistry Ph.D., University of Rochester Medical School, Rochester, NY
1993, M.S. Biochemistry, University of Rochester Medical School, Rochester, NY
1979, Doctor of Medicine, University of Puerto Rico Medical School, San Juan, PR
1975, Bachelor in Science (Magnum cum Laude), University of Puerto Rico, San Juan, PR
1986, Fellowship, Gynecological Oncology, University of Michigan Medical School, Ann Arbor, Michigan
1983, Residency, Obstetrics and Gynecology, Rutgers Medical School, Cooper University Hospital Camden, New Jersey
1983, Internship, Obstetrics and Gynecology, Rutgers Medical School, Cooper University Hospital Camden, New Jersey
2019-present, Professor, Division of Gynecologic Oncology, Department of Surgery, City of Hope, Duarte, California
2019-present, Vice Chair of Faculty Development, City of Hope, Duarte, California
2008-2019, Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School
Professor of Obstetrics and Gynecology with tenure2017-2019, Chief, Division of Gynecologic Oncology, Rutgers CINJ
2016-2017, Acting Chief, Division of Gynecologic Oncology, Rutgers CINJ
2012-present, Director of Precision Medicine, Rutgers CINJ
2012-2017, Director, Biorepository Services, Rutgers CINJ
2000-2012, Chief, Gynecologic Oncology, CINJ
2000-2008, Associate Professor of Obstetrics and Gynecology with tenure, Department of Obstetrics, Gynecology and Reproductive Sciences UMDNJ/Robert Wood Johnson Medical School
1996-2000, Associate Professor of Obstetrics and Gynecology, Department of Obstetrics and Gynecology University of Rochester Medical School
1996-2000, Associate Professor of Microbiology and Immunology, Department of Microbiology and Immunology University of Rochester Medical School
1996-2000, Director, Division of Gynecologic Oncology, University of Rochester Medical School
1986-1995, Assistant Professor of Obstetrics and Gynecology, Department of Obstetrics and Gynecology Albert Einstein College of Medicine
Awards & Memberships
Awards
2021, Carol Emmott Fellowship
2021, Los Angeles Magazine Top Doctors 2020
2016, Selected as a Top Doctor for Cancer in Inside New Jersey Magazine
2016, Invited to serve on AACR Annual Meeting Scientific Program Committee
2016, Selected as one of New York Metro Area’s Top Doctors by Castle Connolly Medical, Ltd.
2015, Invited to be a member of the BIONJ DX Precision Medicine Committee
2015, Selected as one of Jersey’s 1992 Top Doctor Inside New Jersey Magazine
2015, Selected as a Top Doctor for Cancer in Inside New Jersey Magazine
2015, Selected as Co-Chair GYN Clinical Trials Working Group
2015, Selected as a Top Doctor for Women’s Health in Inside New Jersey Magazine
2014, Selected as one of the Best Doctors in America by Best Doctors, Inc. USA
2014, Selected as a Top Doctor for Women featured in Inside New Jersey Magazine
2014, Selected as a Top Doctor for Cancer Care featured in Inside New Jersey Magazine
2014, Selected as a Top Doctor for Women’s Health featured in Inside New Jersey Magazine
2014, Selected as one of New York Metro Area’s Top Doctors by Castle Connolly Medical, Ltd.
2014, Selected as one of New Jersey’s Outstanding Physician by Castle Connolly Medical, Ltd.
2013, Selected as one of New York Metro Area’s Top Doctors by Castle Connolly Medical, Ltd.
2011, Selected as a NJ Top Doctor for Women’s Health by NJTopDocs.com
2009, Selected as one of the Outstanding NJ Physicians by Castle Connolly Medical, Ltd. Appeared in Inside New Jersey Magazine
2009, Nominated for Woman of the Year in Medicine & Healthcare by the American Biographical Institute Board of International Research
2008, Invited to speak at the 2008 AACR Jane Cook Wright Lectureship and review the scientific work of the winner
2007, Invited to serve on the RCMI-IdeA review Committee (NIH COBRE Awards)2007, Invited to be the Chair for the Selection Committee for the AACR-Minorities in Cancer Research
2007-2012, Invited to draft the Gynecologic Chapter of The NJ Comprehensive Cancer Control Plan
2007, Selected by Rush Holtz to represent women in leadership of NJ in Washington, DC
2006, Consultant to Senator Buono of NJ regarding new legislature on ovarian cancer prevention
2006, Invited to be a member of the Ovarian Cancer Workshop as part of the Cancer Control
2006, Nominated to the Gynecologic Cancer Steering Committee (NCI)
2005-2006, Plan/Invited to be a co-chair at a Progress Review group by NCI (AYAO PRG)
2001, Invited Speaker to the International Conference on the Extracellular Matrix of the Female Reproductive Tract
2000, Invited by the Office on Women’s Health (NIH) to participate on a workshop about barriers to health care access
2000, Invited by the Office on Women’s Health (NIH) to participate on a Scientific Workshop on Lesbian’s Health
Memberships
2017-present, Member, Molecular Tumor Board, American Society of Clinical Oncologists (ASCO) Targeted Agent and Profiling Utilization Registry Study
2015-present, Member, Society for Immunotherapy of Cancer, American Association for Cancer Research (AACR) Annual Meeting Scientific Program Committee 2016
2015-present, Co-chair GYN Clinical Trials Working Group
2015-present, Member, BIG Ten Cancer Research Consortium
2015-May 2020, Member, ORIEN Total Cancer Care Protocol Advisory Committee
2015-present, Member, BIONJ DxPM Committee
2007-2008, AACR Chairperson Selection Committee for AACR Minorities in Cancer Research /Jane Cooke Wright Lectureship
2007-2008, Gynecology Track Leader
2006, Program Committee, AACR
2005, Member, International Gynecologic Cancer Society
2005-2008, Cancer Education Committee
2004-2005, AACR Scientist Survivor Committee
2003, Membership Committee, ASCO
2001-2007, ASCO/AACR Methods in Clinical Cancer Research Program Committee
1988-present, Member, Society of Gynecologic Oncology
1998, Member, American Radium Society
1988, Fellow, American College of Obstetrics and Gynecology
Publications
- Jun Lee, E. H., Cullen, C., Murad, J. P., Gumber, D., Park, A. K., Yang, J., Stern, L. A., Adkins, L. N., Dhapola, G., Gittins, B., Chung-Chang, W., Martinez, C., Woo, Y., Cristea, M., Rodriguez-Rodriguez, L., Ishihara, J., Lee, J. K., Forman, S. J., Wang, L. D., & Priceman, S. J. (2023). Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. bioRxiv: the preprint server for biology, 2023.01.06.522784. https://doi.org/10.1101/2023.01.06.522784
- Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, Lee P, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, Kebria M, Hakim A, Ruel N, Stewart DB, Wang EW, Paz BI, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L. Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. JCO Precis Oncol. 2022 Mar;6:e2100239. doi: 10.1200/PO.21.00239. Erratum in: JCO Precis Oncol. 2022 Jun;6:e2200296. PMID: 35357903; PMCID: PMC8984280.
- Zhao, Q., Kohut, A., Li, YJ., Martincuks, A., Austria, T., Zhang, C., Lugo Santiago, N., Martinez Borrero, R., Rodriguez-Rodriguez, L., & Yu, H. (2022). Niraparib-induced STAT3 inhibition increases its antitumor effects. Front Oncol. 2022 Oct 17;12:966492. doi: 10.3389/fonc.2022.966492. eCollection 2022.PMID: 36324587
- Kohut A, Whitaker T, Walter L, Li SY, Han E, Lee S, Wakabayashi MT, Dellinger TH, Han ES, Rodriguez-Rodriguez L, Chung C. Feasibility of combining pelvic reconstruction with gynecologic oncology-related surgery. Int Urogynecol J. 2022 May 2. doi: 10.1007/s00192-022-05212-7. Epub ahead of print. PMID: 35501570.
- Tian L, Xu B, Teng KY, Song M, Zhu Z, Chen Y, Wang J, Zhang J, Feng M, Kaur B, Rodriguez-Rodriguez L, Caligiuri MA, Yu J.Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. Clin Cancer Res. 2021 Oct 13: clincanres.1248.2021. doi: 10.1158/1078-0432.CCR-21-1248. Online ahead of print. PMID: 34645647
- Yue E, Yang G, Yao Y, Wang G, Mohanty A, Fan F, Zhao L, Zhang Y, Mirzapoiazova T, Walser TC, Rodriguez-Rodriguez L, Fong Y, Salgia R, Wang EW. Cancers (Basel). Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment.2021 Aug 24;13(17):4265. doi: 10.3390/cancers13174265. PMID: 34503075 ;
- Raoof M, Malhotra G, Kohut A, O'Leary M, Frankel P, Tran T, Fakih M, Chao J, Lim D, Woo Y, Paz IB, Lew M, Cristea MC, Rodriguez-Rodriguez L, Fong Y, Blakely A, Whelan R, Reymond MA, Merchea A, Dellinger TH. PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial. Ann Surg Oncol. 2021 Aug 13. doi: 10.1245/s10434-021-10505-0. Online ahead of print. PMID: 34387765
- Kohut A, Earnhardt MC, Cuccolo NG, Kim CS, Song M, Girda E, De Meritens AB, Stephenson R, Balica A, Leiser A, Demissie K, Rodriguez-Rodriguez L. Evaluating unplanned readmission and prolonged length of stay following minimally invasive surgery for endometrial cancer. Gynecol Oncol. 2020 Jan;156(1):162-168. doi: 10.1016/j.ygyno.2019.08.023. PMID: 31839339.
- Martincuks A, Li PC, Zhao Q, Zhang C, Li YJ, Yu H, Rodriguez-Rodriguez L. CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3. Front Oncol. 2020 Dec 1;10:589601. doi: 10.3389/fonc.2020.589601. PMID: 33335857; PMCID: PMC7736609.
- Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger T, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez-Rodriguez L. Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. J Clin Med. 2020 Sep 1;9(9):2830. doi: 10.3390/jcm9092830. PMID: 32882942; PMCID: PMC7565288.
- Martincuks A, Li PC, Zhao Q, Zhang C, Li YJ, Yu H, Rodriguez-Rodriguez L. CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3. Front Oncol. 2020 Dec 1;10:589601. doi: 10.3389/fonc.2020.589601. PMID: 33335857; PMCID: PMC7736609.
- Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Goodman MT, Modugno F, Ness RB, Moysich KB, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Berchuck A, Cramer DW, Bandera EV, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod SA, McLaughlin JR, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Lindström S, Terry KL. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2019 Jun 1;48(3):822-830. doi: 10.1093/ije/dyz113. PMID: 31211375
To view a full list of Lorna Rodriguez-Rodriguez's publications, please visit NCBI publications.